Stay updated on NSCLC Carboplatin+Pemetrexed+Bevacizumab+/-Atezolizumab Clinical Trial
Sign up to get notified when there's something new on the NSCLC Carboplatin+Pemetrexed+Bevacizumab+/-Atezolizumab Clinical Trial page.

Latest updates to the NSCLC Carboplatin+Pemetrexed+Bevacizumab+/-Atezolizumab Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe clinical trial page presents details for a Phase II study of combination treatments for Stage IV non-squamous lung cancer, including eligibility criteria, study arms, outcome measures, locations, and record dates. It also indicates that the study is active but no longer recruiting.SummaryDifference49%

- Check18 days agoChange DetectedThe website footer now shows revision v3.8.0 instead of v3.7.2, while the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedA banner announces NIH website transition updates and says that “Super Intelligence” (SI) is replacing “Artificial Intelligence” (AI) in federal agency content.SummaryDifference1%

- Check32 days agoChange DetectedThe footer revision changed from v3.7.1 to v3.7.2; the page continues to display a 403 error.SummaryDifference0.2%

- Check39 days agoChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check60 days agoChange DetectedThe page now shows a 403 Forbidden error, indicating access is blocked. The update adds the 403 page structure and removes the extensive study record content and history sections, leaving an error-focused view instead of the usual study details.SummaryDifference19%

Stay in the know with updates to NSCLC Carboplatin+Pemetrexed+Bevacizumab+/-Atezolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the NSCLC Carboplatin+Pemetrexed+Bevacizumab+/-Atezolizumab Clinical Trial page.